BALF2, which encodes the major DNA-binding protein of Epstein-Barr virus (EBV), is expressed during the early stage of the lytic cycle. The location of the BALF2 promoter was identified by primer extension, which indicated that the transcription start is located at nucleotide 164,782 of the EBV genome. Transfection analyses revealed that, similar to other EBV early promoters, the BALF2 promoter is activated by the EBV-encoded transcription factors Rta and Zta. The promoter is also synergistically activated if both transcription factors are present in B lymphocytes and in epithelial cells. Deletion analysis and electrophoretic mobility-shift assay revealed that the region between nucleotides N134 and N64 contains Zta-response elements and the region between nucleotides N287 and N254 contains Rta-response elements. This study demonstrates the importance of Rta and Zta in regulating the transcription of EBV early genes.
N134 and N64 contains Zta-response elements and the region between nucleotides N287 and N254 contains Rta-response elements. This study demonstrates the importance of Rta and Zta in regulating the transcription of EBV early genes.
Epstein-Barr virus (EBV) is a human herpesvirus which infects lymphoid and epithelial cells. After infecting B lymphocytes, EBV immortalizes the cells and the viral genome is maintained as an episome under latent conditions (Nonoyama & Pagano, 1972) . EBV can be switched from a latent to a lytic cycle when latently infected cells are exposed to extracellular stimuli, including 12-O-tetradecanoylphorbol 13-acetate (TPA), sodium butyrate, calcium ionophores and anti-immunoglobulin (Luka et al., 1979 ; Takada & zur Hausen, 1984 ; zur Hausen et al., 1978) . Such treatment causes cells to express two EBV-encoded transcription factors, Rta and Zta. These two proteins act cooperatively to activate the transcription of EBV early genes, including BALF5, BHLF1, BHRF1 and BMRF1 (Chavrier et al., 1989 ; Chevallier-Greco et al., 1989 ; Cox et al., 1990 ; Furnari et al., 1992 ; Holley-Guthrie et al., 1990) . Of these genes, BALF5 and BMRF1 are involved in EBV lytic DNA replication (Fixman et al., 1992) . During the early stage of the EBV lytic cycle, EBV also transcribes BALF2, which encodes a Author for correspondence : Shih-Tung Liu.
Fax j886 3 328 0292. e-mail cgliu!mail.cgu.edu.tw single-stranded DNA-binding protein called mDBP (Tsurumi et al., 1996) . A related investigation indicated that the EBV strain Raji, in which BALF2 is deleted, cannot replicate its DNA during the lytic cycle (Polack et al., 1984) ; this can be corrected by using a functional BALF2 present in trans (Decaussin et al., 1995) , indicating that mDBP is crucial for EBV DNA lytic replication.
The transcription start site of BALF2 mRNA was determined by primer extension with a primer (PE261) which is complementary to the 5h region of BALF2 (nucleotides 164,744 to 164,721 of the EBV genome) (Fig. 1 A) . Primer extension was performed according to a previously described method with 100 µg of total RNA isolated from P3HR1 cells that had been treated with 30 ng\ml of TPA and 3 mM sodium butyrate for 36 h. This analysis identified a cDNA product 62 nucleotides long, indicating that the j1 site is located at nucleotide 164,782 of the EBV genome. This transcription start site was also confirmed by using a primer complementary to the region between nucleotides 164,644 and 164,621 of the EBV genome. RNA isolated from P3HR1 cells that had not been treated with TPA and sodium butyrate did not produce this 62 nucleotide cDNA ( Fig. 1 B, lane 2) . Upstream from the transcription start site, the BALF2 promoter contains a TATA sequence and two putative AP-1-binding sites (Fig. 1 A) .
We constructed a reporter plasmid, pSSB (Fig. 2 C) , to analyse the BALF2 promoter. This plasmid was constructed by inserting a PCR fragment containing the sequence between k1837 and j12 of BALF2 into the BglII site of pGL2-Basic (Promega). This plasmid was transfected into an EBV-positive cell line, P3HR1 ; the luciferase activity exhibited by the plasmid was measured 36 h after transfection (de Wet et al., 1987) . This plasmid exhibited a background level of luciferase activity if the cells were maintained under latent conditions. However, the activity increased 103-fold if the cells were treated with TPA and sodium butyrate, indicating that the promoter is active under lytic conditions. Rta and Zta regulate the transcription of EBV early genes Furnari et al., 1992 ; HolleyGuthrie et al., 1990) . Therefore, we investigated whether or not these two transcription factors also activate the BALF2 promoter. Plasmids pCMV and pSSB were co-transfected into EBV-negative Akata cells. Because pCMV, a cloning vector, does not contain a gene that would activate the BALF2 promoter, the luciferase activity exhibited by pSSB was at a background level. On the other hand, luciferase activity increased 101-fold when the cells were cotransfected with pSSB and a plasmid (pCMV-Z) which expresses Zta (Fig. 2 A) , indicating that Zta activates the BALF2 promoter. Luciferase activity increased 31-fold when the cells were cotransfected with pSSB and a plasmid (pCMV-R) which expresses Rta (Fig.  2 A) , indicating that Rta also activates the BALF2 promoter. The cells were also co-transfected with pSSB and a plasmid (pCMV-RZ) which expresses both Rta and Zta. The presence of pCMV-RZ in the cells increased luciferase activity 1161-fold (Fig. 2 A) . An earlier study demonstrated that pCMV-RZ transcribes a BRLF1-BZLF1 bicistronic mRNA and that both Rta and Zta are efficiently translated from this bicistronic mRNA in EBV-negative Akata cells (Chang et al., 1998 b) . Therefore, a 1161-fold activation of the BALF2 promoter by pCMV-RZ indicates that the BALF2 promoter is synergistically activated by Rta and Zta. The BALF2 promoter was also activated by Rta and Zta in an epithelial cell line, C33A (Fig.  2 B) . Plasmid pCMV-Z activated the promoter 2-fold ; pCMV-R activated the promoter 3-fold ; pCMV-RZ activated the promoter 300-fold (Fig. 2 A) . Next, we generated deletions in pSSB to analyse the function of the BALF2 promoter (Fig. 2 C) . Deletion ∆1771 was generated by SmaI\SacII double digestion ; ∆1459 by SmaI\NruI double digestion ; ∆864 by SmaI\PvuII double digestion ; and ∆331 by SmaI\BssHII double digestion. In P3HR1 cells, these deletions did not significantly lower the luciferase activity under lytic conditions (Fig. 2 C) . We also deleted the regions upstream from the AatII site (∆134) and from nucleotide k64 (∆64), which was generated by inserting the sequence between nucleotides k64 and j12 into the BglII site of pGL2-Basic. Under lytic conditions in P3HR1 cells, deletion ∆134 decreased the promoter activity by approximately 90 % ; ∆64 decreased the activity by 95 % (Fig. 2 C) , demonstrating that the region downstream from nucleotide k331 is necessary for BALF2 transcription. Co-transfection experiments also revealed that pCMV-Z activated the luc transcription of ∆134 but did not activate the transcription of ∆64 (Fig. 2 D) , suggesting that the region between nucleotides k134 and k64 contains sequence necessary for activation by Zta. Transcription of luc by ∆331 was activated by pCMV-R. However, mutants ∆134 and ∆64 were not activated by pCMV-R, indicating that the region between nucleotides k331 and k134 contains element necessary for activation by Rta (Fig. 2 E) . Deletion analysis revealed that the region between the BssHII (nucleotide k331) and AatII (nucleotide k134) sites probably contains sequences requires for activation by Rta (Fig. 2 E) . Therefore, this fragment was inserted into the SmaI site of a reporter plasmid (pGL2-Promoter) (Promega) which contains luc transcribed from an SV40 promoter. The resulting plasmid [BA(j)] was cotransfected with pCMV-R into EBVnegative Akata cells. Results showed that pCMV-R activated the activity of the SV40 promoter by 5n5-fold. Inserting the DNA fragment in the opposite orientation, BA(k), did not affect activation by Rta (data not shown), implying that the BA fragment functions as an enhancer. DNA fragments containing the sequence between nucleotides k287 and k134, k254 and k134 or k185 and k134 were amplified by PCR with Fig. 2 . Analysis of the BALF2 promoter. EBV-negative Akata cells (A) and C33A cells (B) were co-transfected with pSSB and pCMV-R (R), pCMV-Z (Z) or pCMV-RZ (RZ). The promoter activity was examined in P3HR1 cells treated (white bars) or untreated (black bars) with TPA and sodium butyrate (C). The numbers represent the nucleotide positions relative to the transcription start site. EBV-negative Akata cells were also co-transfected with pCMV-Z (D) or pCMV-R (E). EBV-negative Akata cells were co-transfected with 5 µg of pCMV-R, 5 µg of an SV40-reporter plasmid containing sequences covering the region between nucleotides k334 and k134 and 5 µg of pSV-β-gal. β-Galactosidase activity in 2 µl of cell lysate was measured using a Galacto-Light kit (Tropix), and was used to normalize the relative light unit values exhibited by the cells (F). For (A) the average fold-activation, relative to the value obtained from a co-transfection experiment with pSSB and the cloning vector pCMV, is presented. Each transfection experiment was repeated at least three times, and each sample in the experiment was prepared in duplicate.
primers SSB-306 (5h GAATTCGGGTGGTGCTGTGCTACA) and SSB-PR, SSB-267 (5h GAATTCGAAACTACCTGGA-TGA) and SSB-PR, and SSB-200 (5h GAATTCTATCGCAG-ACTCTGGT) and SSB-PR, respectively. These fragments were digested with AatII, repaired with T4 DNA polymerase and inserted into the SmaI site upstream from an SV40 promoter in pGL2-Promoter (Promega) to generate deletion mutants ∆287, ∆254 and ∆185. Transfection analysis revealed that deleting the region between nucleotides k331 and k287 (∆287) (Fig. 2 F) did not affect the luciferase activity (Fig. 2 F) . Deleting the region between nucleotides k331 and k254 Fig. 3 . Electrophoretic mobility-shift assay. A probe covering the region between nucleotides k134 and k64 (A) was used for binding analysis (lane 1). ZRE (lane 2) or RRE (lane 3) oligonucleotides, or an antibody against Zta (lane 4), were added to the binding mixture. RRE (5h CCTGTGCCTTGTCCCGTGGACAATGTCCC) was synthesized according to the DR1 sequence of the BHRF1 promoter (Gruffat & Sergeant, 1994) ; ZRE was synthesized according to a Zta-binding sequence (5h CTAGCTCACCTTGAGCAATTTGGTCTAGAA) in the BHRF1 promoter (Chang et al., 1990) . Three probes covering the regions from nucleotides k287 to k254, k254 to k185 and k185 to k134 were used to study the binding of the BALF2 promoter to recombinant GST-Rta protein (B). DNA fragments containing the regions from nucleotides k254 to k185 and from k185 to k134 were amplified by PCR with endlabelled primers. The region between k287 and k254 was generated by annealing two complementary synthetic oligonucleotides. GST protein prepared from E. coli was used as a control. The arrow indicates the shifted band ; ' S ' indicates the supershifted band. Recombinant Rta protein prepared from E. coli was used to generate Rta antibody.
(∆254) and between nucleotides k331 and k185 (∆185) decreased luciferase activity by 50 and 70 % (Fig. 2 F) , respectively.
A DNA fragment containing the region between nucleotides k134 and k64 was used as a probe to examine the binding of Zta. The DNA was incubated with cell extract prepared from P3HR1 cells treated with TPA and sodium butyrate. Electrophoretic mobility-shift assay (EMSA) revealed that proteins in the cell extract bound to this DNA fragment (Fig. 3 A, lane 1) . Adding a DNA fragment containing an Rta-CHEJ response element (RRE) did not compete against the binding (Fig. 3 A, lanes 3) . On the other hand, adding an excessive amount of Zta-response element (ZRE) to the binding mixture prevented binding (Fig. 3 A, lane 2) . A supershifted band appeared when antibody against Zta was added to the binding mixture (Fig. 3 A, lane 4) . According to computer analysis the ZRE is probably located between nucleotides k65 and k71 (Fig. 1 A) . Since deletion analysis revealed that the region between nucleotides k287 and k185 may contain RRE (Fig.  2 F) , we used DNA fragments covering this region to examine if Rta binds to the fragments. Results showed that recombinant GST-Rta but not GST bound to the region between nucleotides k287 and k254, indicating that this region contains an RRE. The band was supershifted by antibody against Rta (Fig. 3 B) . Our results also demonstrated that GST-Rta does not bind to the fragments covering the region between nucleotides k254 and k185 and the region between k185 and k134.
In conclusion, we have identified the j1 site of BALF2 mRNA by primer extension. Results indicated that, similar to other EBV early genes, transcription of BALF2 is synergistically activated by Rta and Zta. BALF2 is a gene required for EBV lytic replication. Our results showed that BALF2 is regulated by the same transcription factors that regulate the transcription of other EBV early genes, allowing these early gene products to be expressed simultaneously for EBV DNA replication.
